New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it will present additional data from the pivotal Phase 3 ...
Clarksburg-Weston WDTV on MSN3h
WVU Medicine helps gives answers to a West Virginia Women who has a rare illness
Twenty-seven-year-old Daniela powers a native of West Virginia. Since 20222, she has experiencing unexplained rashes and ...
Astria Therapeutics: A High-Conviction Bet On HAE
Astria advances innovative therapies for hereditary angioedema and atopic dermatitis. Strong cash position supports pivotal ...
PMLiVE6d
EC approves CSL’s Andembry to prevent hereditary angioedema attacks
The European Commission (EC) has approved CSL’s Andembry (garadacimab) to prevent attacks of hereditary angioedema (HAE) in ...
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present three ...
pharmaphorum6d
EU approves CSL's once-monthly HAE drug Andembry
CSL has been given approval by the European Commission for Andembry, the first once-monthly preventive therapy for the ...
Ionis Pharmaceuticals reports Q4 EPS (66c), consensus (84c)
Reports Q4 revenue $$227.00M, consensus $140.95M.”With the recent launch of our first independent medicine, TRYNGOLZA for familial ...
PharmaTimes7d
Andembry treatment approved across Europe
Global biotechnology leader CSL has announced that the European Commission (EC) has approved ANDEMBRY (garadacimab), the ...